Zydus Lifesciences has entered into an exclusive agreement with Synthon BV, a Dutch company, to develop, license, supply, and commercialize a novel oncology product. The product is intended to address an unmet need in the market and has the potential to reach a $1.5 billion market size in the US alone. Under the agreement, Synthon will be responsible for developing, manufacturing, and supplying the finished product, while Zydus will focus on submitting a New Drug Application (NDA) and commercializing the product in the US. The product is expected to be filed in 2026 and offers several advantages, including reduced pill burden, flexibility for dose adjustment, and enhanced patient compliance.
This partnership is seen as a strategic move by both companies, with Zydus Lifesciences looking to expand its presence in the oncology space and Synthon BV building on its capabilities in complex product development. Zydus Lifesciences’ MD, Sharvil Patel, highlighted the importance of the partnership in bringing access to high-need therapy areas, while Synthon BV’s CEO, Anish Mehta, emphasized the company’s expertise in developing complex and clinically differentiated products.
The agreement is a significant development for both companies, with the potential to generate significant revenue and expand their global reach. The agreement also demonstrates the success of the two companies in partnering to bring innovative treatments to patients. With the global pharmaceutical market expected to continue growing, this partnership is likely to be a significant step forward for both Zydus Lifesciences and Synthon BV, and ultimately, patients suffering from oncological diseases.